Logo image of TEM

TEMPUS AI INC (TEM) Stock Fundamental Analysis

USA - NASDAQ:TEM - US88023B1035 - Common Stock

90.67 USD
-1.78 (-1.93%)
Last: 10/21/2025, 9:44:06 AM
Fundamental Rating

3

Taking everything into account, TEM scores 3 out of 10 in our fundamental rating. TEM was compared to 57 industry peers in the Life Sciences Tools & Services industry. TEM may be in some trouble as it scores bad on both profitability and health. TEM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TEM has reported negative net income.
In the past year TEM has reported a negative cash flow from operations.
In the past 5 years TEM always reported negative net income.
TEM had a negative operating cash flow in each of the past 5 years.
TEM Yearly Net Income VS EBIT VS OCF VS FCFTEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

TEM has a Return On Assets (-12.29%) which is comparable to the rest of the industry.
The Return On Equity of TEM (-64.52%) is worse than 71.93% of its industry peers.
Industry RankSector Rank
ROA -12.29%
ROE -64.52%
ROIC N/A
ROA(3y)-60.21%
ROA(5y)-54.09%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TEM Yearly ROA, ROE, ROICTEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

TEM's Gross Margin of 60.73% is amongst the best of the industry. TEM outperforms 80.70% of its industry peers.
TEM's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TEM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.22%
GM growth 5Y16.28%
TEM Yearly Profit, Operating, Gross MarginsTEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

3

2. Health

2.1 Basic Checks

TEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for TEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TEM Yearly Shares OutstandingTEM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
TEM Yearly Total Debt VS Total AssetsTEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 5.65 indicates that TEM is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.65, TEM belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
A Debt/Equity ratio of 2.58 is on the high side and indicates that TEM has dependencies on debt financing.
TEM's Debt to Equity ratio of 2.58 is on the low side compared to the rest of the industry. TEM is outperformed by 85.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.58
Debt/FCF N/A
Altman-Z 5.65
ROIC/WACCN/A
WACC10.46%
TEM Yearly LT Debt VS Equity VS FCFTEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

TEM has a Current Ratio of 1.54. This is a normal value and indicates that TEM is financially healthy and should not expect problems in meeting its short term obligations.
TEM has a Current ratio of 1.54. This is in the lower half of the industry: TEM underperforms 73.68% of its industry peers.
A Quick Ratio of 1.43 indicates that TEM should not have too much problems paying its short term obligations.
TEM's Quick ratio of 1.43 is on the low side compared to the rest of the industry. TEM is outperformed by 61.40% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.43
TEM Yearly Current Assets VS Current LiabilitesTEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

TEM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.61%, which is quite impressive.
TEM shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.84%.
TEM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 62.05% yearly.
EPS 1Y (TTM)85.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.08%
Revenue 1Y (TTM)59.84%
Revenue growth 3Y39.06%
Revenue growth 5Y62.05%
Sales Q2Q%89.57%

3.2 Future

The Earnings Per Share is expected to grow by 29.06% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 40.15% on average over the next years. This is a very strong growth
EPS Next Y70.68%
EPS Next 2Y40.88%
EPS Next 3Y29.06%
EPS Next 5YN/A
Revenue Next Year80.87%
Revenue Next 2Y49.6%
Revenue Next 3Y40.15%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TEM Yearly Revenue VS EstimatesTEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
TEM Yearly EPS VS EstimatesTEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TEM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TEM Price Earnings VS Forward Price EarningsTEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K -2K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TEM Per share dataTEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

TEM's earnings are expected to grow with 29.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.88%
EPS Next 3Y29.06%

More info and screens

0

5. Dividend

5.1 Amount

TEM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEMPUS AI INC

NASDAQ:TEM (10/21/2025, 9:44:06 AM)

90.67

-1.78 (-1.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-06 2025-11-06
Inst OwnersN/A
Inst Owner Change0.1%
Ins OwnersN/A
Ins Owner Change-0.62%
Market Cap15.75B
Analysts77.89
Price Target77.01 (-15.07%)
Short Float %26.96%
Short Ratio2.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.58%
Min EPS beat(2)10.18%
Max EPS beat(2)16.99%
EPS beat(4)4
Avg EPS beat(4)14.69%
Min EPS beat(4)10.18%
Max EPS beat(4)20.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.49%
Min Revenue beat(2)2.05%
Max Revenue beat(2)4.94%
Revenue beat(4)2
Avg Revenue beat(4)1.15%
Min Revenue beat(4)-2.18%
Max Revenue beat(4)4.94%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.85%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.05%
EPS NY rev (1m)2.88%
EPS NY rev (3m)-0.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.55
P/FCF N/A
P/OCF N/A
P/B 50.89
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS5.48
BVpS1.78
TBVpS-2.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.29%
ROE -64.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.73%
FCFM N/A
ROA(3y)-60.21%
ROA(5y)-54.09%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.22%
GM growth 5Y16.28%
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 2.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.05%
Cap/Sales 2.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.43
Altman-Z 5.65
F-Score4
WACC10.46%
ROIC/WACCN/A
Cap/Depr(3y)74.55%
Cap/Depr(5y)66.22%
Cap/Sales(3y)5.14%
Cap/Sales(5y)5.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.08%
EPS Next Y70.68%
EPS Next 2Y40.88%
EPS Next 3Y29.06%
EPS Next 5YN/A
Revenue 1Y (TTM)59.84%
Revenue growth 3Y39.06%
Revenue growth 5Y62.05%
Sales Q2Q%89.57%
Revenue Next Year80.87%
Revenue Next 2Y49.6%
Revenue Next 3Y40.15%
Revenue Next 5YN/A
EBIT growth 1Y65.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year102.3%
EBIT Next 3Y42.48%
EBIT Next 5YN/A
FCF growth 1Y15.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.8%
OCF growth 3YN/A
OCF growth 5YN/A